- freely available
Recent Developments in Preclinical DNA Vaccination
AbstractThe advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. One is about their weak immunogenicity in humans. To overcome this problem, various genetic adjuvants, electroporation, and prime-boost methods have been developed preclinically, which are reviewed here.
Share & Cite This Article
Export to BibTeX | EndNote
MDPI and ACS Style
Okuda, K.; Wada, Y.; Shimada, M. Recent Developments in Preclinical DNA Vaccination. Vaccines 2014, 2, 89-106.View more citation formats
Okuda K, Wada Y, Shimada M. Recent Developments in Preclinical DNA Vaccination. Vaccines. 2014; 2(1):89-106.Chicago/Turabian Style
Okuda, Kenji; Wada, Yoshiyuki; Shimada, Masaru. 2014. "Recent Developments in Preclinical DNA Vaccination." Vaccines 2, no. 1: 89-106.